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Abstract
Background: All the enzymatic factors/cofactors involved in nitric oxide (NO) metabolism have been recently found in red
blood cells. Increased oxidative stress impairs NO bioavailability and has been described in plasma of coronary artery
disease (CAD) patients. The aim of the study was to highlight a potential dysfunction of the metabolic profile of NO in red
blood cells and in plasma from CAD patients compared with healthy controls.
Methods: We determined L-arginine/NO pathway by liquid-chromatography tandem mass spectrometry and high
performance liquid chromatography methods. The ratio of oxidized and reduced forms of glutathione, as index of oxidative
stress, was measured by liquid-chromatography tandem mass spectrometry method. NO synthase expression and activity
were evaluated by immunofluorescence staining and ex-vivo experiments of L-[15N2]arginine conversion to L-[
15N]citrulline
respectively.
Results: Increased amounts of asymmetric and symmetric dimethylarginines were found both in red blood cells and in
plasma of CAD patients in respect to controls. Interestingly NO synthase expression and activity were reduced in CAD red
blood cells. In contrast, oxidized/reduced glutathione ratio was increased in CAD and was associated to arginase activity.
Conclusion: Our study analyzed for the first time the whole metabolic pathway of L-arginine/NO, both in red blood cells and
in plasma, highlighting an impairment of NO pathway in erythrocytes from CAD patients, associated with decreased NO
synthase expression/activity and increased oxidative stress.
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Introduction
Nitric oxide (NO) is a signaling molecule that has a pivotal role
in regulating vascular tone. It promotes several beneficial effects in
the vasculature, favoring vasodilatation and inhibiting smooth
muscle cells proliferation, enhancing fibrinolysis, and inhibiting
some activities of circulating blood cells, as platelet aggregation
and leukocyte adhesion [1,2]. NO is synthesized by a family of NO
synthases (NOSs) through the conversion of L-arginine (Arg) to L-
citrulline (Cit). Endogenous Arg analogues, the dimethylarginines
(DMAs), are able to inhibit NO synthesis. In particular,
asymmetric dimethylarginine (ADMA) competes with the sub-
strate at the catalytic site of NOS and symmetric dimethylarginine
(SDMA) interacts with the transport of Arg into the cells, via the
transporter for cationic amino acids (CAT). Increased plasma
levels of these DMAs have been described in coronary artery
disease (CAD) [3].
Endothelial cells are the main producers of NO, but other
circulating cells are involved in NO synthesis, i.e. platelets,
monocytes and red blood cells (RBCs). Initially, it has been
observed that RBCs are able to scavenge NO synthesized by
endothelial cells, providing the transport of oxidized (nitrite/
nitrate) and nitrosylated (SNO-Hb and HbNO) forms of NO in
the bloodstream and their local delivery [4]. More recently, it has
been shown that RBCs are able to synthesize NO through a
constitutive type of NOS (RBC-NOS), which is similar to the
enzyme found in endothelial cells [5].
All the enzymes involved in DMAs metabolism (synthesis or
catabolism) [6] as well as the CAT have been found in RBCs [7].
In addition, large amounts of ADMA and SDMA have been
evidenced into RBC proteins [8,9].
Some authors have investigated the role of RBC-derived NO in
the regulation of blood flow [10] and platelet function [5,11]. Even
if, up to now, no clinical implications of the alteration of this NO
source have been depicted, a stimulation or an inhibition of RBC-
NOS results in a decrease or an increase of platelet aggregation,
respectively [5]. RBC-derived NO also acts in an autocrine
manner by modulating the deformability of RBCs thus favoring
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their passage through the capillaries and improving the blood flow
in the microcirculation [12,13]. Recently, RBC-NOS activity has
been reported to be impaired in CAD patients [14].
Endothelial dysfunction, with reduced NO bioavailability, is a
pathological condition frequently occurring in CAD patients [15].
An increased oxidative stress may reduce the NO bioavailability
through an impairment of the NO synthesis and through the
inactivation of the NO produced by transforming it into
peroxynitrate. Oxidative stress, resulting from the imbalance
between oxidant factors and antioxidant defense systems, has been
previously reported in CAD patients [16,17].
In this study, we hypothesized that reduction of NO biosynthesis
occurs in CAD RBCs and that it may be ascribed to a
dysregulated Arg metabolism and/or increased oxidative stress.
To this aim we investigated the synthetic and metabolic profile of
NO and oxidative stress both in RBCs and in plasma from healthy
subjects and from patients affected by CAD.
Methods
Ethical approval
This observational study was conducted with the approval of the
local ethics research committee of Centro Cardiologico Monzino
(nu S1687/610) and written informed consent to participate was
obtained from all subjects. The investigation conformed to the
principles outlined in the Declaration of Helsinki.
Study population
Patients with stable effort angina or inducible ischaemia and
documented CAD were enrolled. Eligibility of patients was based
on the presence of stable exertional angina and positive stress test,
as judged by at least 1.5 mm horizontal or down-sloping ST-
segment depression. Key angiographic inclusion criteria was the
evidence of .75% narrowing in at least one major coronary
vessel, with normal left ventricular ejection fraction ($50%)
assessed by two-dimensional echocardiography. Patients with a
history of congestive heart failure, significant valvular diseases,
hypertrophic cardiomyopathy, vasospastic angina, recent (,6
months) acute coronary syndrome, surgical or percutaneous
revascularization, and those with pacemaker dependency and
atrial fibrillation were excluded. Patients with renal insufficiency
(serum creatinine concentration .1.4 mg/dL), hepatic disease,
recent infection, recent major surgical interventions, immunolog-
ical disorders, chronic inflammatory or neoplastic diseases, were
also excluded. Twenty-two patients met the eligibility criteria.
Twenty healthy subjects without cardiovascular risk factors and
evidence of CAD were enrolled as control group (Ctrl) from those
attending the clinic for global control of cardiovascular risk at
Centro Cardiologico Monzino IRCCS.
Blood collection
Peripheral blood was drawn from the antecubital vein of
patients and controls while fasting, into tubes containing EDTA
(9.3 mM; Vacutainer Systems, Becton Dickinson, Franklin Lakes,
NJ, USA) to obtain whole blood, plasma and erythrocyte samples.
EDTA-anticoagulated blood was centrifuged at 1.200 g for 10 min
at 4uC. Plasma was separated and aliquots were stored at 280uC
until analyses. Aliquots of packed red cells were lysed by cold
deionized water to obtain lysed RBCs and stored at 280uC until
analyses.
Biochemical determinations
L-arginine/NO metabolome. Arg/NO pathway was deter-
mined both in lysed RBCs and in plasma. Arg, ADMA, SDMA,
Cit and L-ornithine (Orn) were simultaneously measured by liquid
chromatography – tandem mass spectrometry (LC-MS/MS) as
previously described [18].
The ratio Arg/(Orn+Cit) as index of global Arg availability
[19,20] and the ratio Orn/Cit as indicator of the relative activity
of arginase and NOS [21] were computed.
Tetrahydrobiopterin. Tetrahydrobiopterin (BH4) concen-
tration was measured in lysed RBCs and in plasma by HPLC
after selective oxidation with iodine, using the method described
by Fukushima and Nixon [22].
Glutathione. Reduced glutathione (GSH) and disulphide
glutathione (GSSG) were measured on whole blood added with
10% trichloroacetic acid in 1 mM EDTA solution to precipitate
proteins and stored at 280uC until analysis. Levels of GSH and
GSSG were assessed by LC-MS/MS method [23]. Levels of GSH
and GSSG were expressed as mmol/g Hb.
RBC-NO synthase expression
Immunofluorescence and confocal microscopy. The
confocal analysis was performed in a subgroup of subjects
(n = 10 per group matched for age and sex, randomly chosen
and representative of the enrolled population). After plasma
separation, an aliquot of RBCs was fixed in 2% paraformaldehyde
at room temperature (RT) for 30 min, stroked on glass and heat
fixed. Non specific reactive sites were blocked with 5% bovine
serum albumin solution containing 0.1% saponin for 30 min at
RT. RBCs were incubated overnight at 4uC with a monoclonal
anti eNOS antibody (2.5 mg/ml; BD Biosciences, Milano, Italy)
followed by washings and incubation with an anti-mouse
conjugated secondary antibody (40 mg/ml; Alexa Fluor488) for
1 hr at RT. The samples were mounted with fluorescent mounting
medium (DAKO, Milano, Italy) and examined by laser scanning
confocal microscope (LSM710, Carl Zeiss, Milano, Italy) using a
636/1.3 oil immersion objective lens. For negative controls, RBCs
were incubated in the absence of primary antibody. Fluorescent
images were captured on confocal microscope connected to a
digital camera using the image processor Zen (Carl Zeiss). For
analysis of immunostaining intensity in RBCs, the grey values of
Ctrl and CAD patients from at least three randomly selected areas
of each smear, were measured. The fluorescence immunostaining
is reported as the mean of grey value subtracted of background
grey value determined on the same smear in the absence of
primary antibody.
In vitro RBC-NO synthase activity
NOS activity in RBCs was measured in a subgroup of age and
sex matched subjects (n = 8 Ctrl and CAD patients, randomly
chosen and representative of the enrolled population). The
enzymatic activity was measured in vitro by the conversion of L-
[15N2]arginine to L-[
15N]citrulline in the presence of the arginase
inhibitor N(omega)-hydroxy-nor-l-arginine (nor-NOHA). Washed
RBCs (106cells/ml) were lysed on ice by cold deionized water (1:1,
v/v) in the presence of protease inhibitors (phenylmethanesulfo-
nylfluoride, 2 mM; leupeptin, 4 mM; aprotinin, 4 mM). Samples
were incubated at 37uC for 2 hr with L-[15N2]arginine (75 mM)
and NOS cofactors in the absence or in the presence of nor-
NOHA (50 mM). The composition of reaction buffer (in mM) was
as follows: Tris-HCl, 250, pH 7.4; CaCl2, 500; BH4, 0.3; flavin
adenine dinucleotide (FAD), 0.1; flavin mononucleotide (FMN),
0.1; nicotinamide adenine dinucleotide phosphate (NADPH), 100.
The reaction was stopped by the addition of 5 volumes of
acetonitrile/methanol (50:50, v/v). Precipitated proteins were
separated by centrifugation at 10.000 g for 15 min at 4uC and
stored at 280uC until analysis. The analytes were measured by
Erythrocyte Synthesis of NO in CAD Patients
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LC-MS/MS and the activity was quantified as the ratio between
the L-[15N]citrulline (mmol/106 cells) and residual L-[15N2]argi-
nine (mmol/106 cells) [21].
Statistical analysis
Twenty subjects per group allowed a statistical power of 90% to
deem as significant a between-group difference in any analyte
approximately equal to one standard deviation, with an alpha
error of 0.05. Variables with skewed distribution were log
transformed before analysis. Patient’s characteristics were com-
pared by T-test. Oxidative stress and Arg/NO pathway variables
were compared between CAD and Ctrl by covariance analysis,
adjusting for age and sex. Immunofluorescence intensity was
compared between groups by repeated measures covariance
analysis, taking into account triplicate measures for each subject.
Unadjusted associations between analyte concentrations were
assessed by bi-variate Pearson correlation; partial correlations
were also computed in order to adjust for the effects of the other
analytes. All analyses were performed by SAS v. 9.2 (SAS Institute
Inc., Cary, NC, USA).
Results
Population
Demographic and clinical characteristics of CAD patients and
controls are reported in Table 1. CAD patients were older and had
higher BMI. There were more hypercholesterolemic and hyper-
tensive subjects among CAD patients, but both LDL cholesterol
and systolic/diastolic pressure values were similar between patients
and Ctrl, as the result of pharmacological treatments.
Assessment of products of the Arg/NO pathway in
plasma and RBCs
In the study we simultaneously measured Arg, Cit, Orn and the
endogenous inhibitors ADMA and SDMA in plasma and in lysed
RBCs from CAD patients and Ctrl by LC-MS/MS (Figure 1 and
2). In plasma (Figure 1A) mean levels of Arg and Cit were
comparable between the two groups, whereas levels of Orn were
higher in CAD patients than in Ctrl. As a consequence, the ratio
Arg/(Orn + Cit), as index of Arg bioavailability, was lower in
CAD than in Ctrl (Figure 1B). In addition the Orn/Cit ratio in
plasma differed significantly in the two groups (Figure 1B),
suggesting different activities of the Arg metabolic enzymes, i.e.
arginase and eNOS. Furthermore, mean levels of ADMA and
SDMA (Figure 1C) were higher in CAD patients than in Ctrl,
whereas the levels of cofactor BH4 (Figure 1D) were lower, the
difference approaching statistical significance.
In RBCs the levels of Arg, Orn and Cit (Figure 2A), and of the
cofactor BH4 (Figure 2D), were comparable between the two
groups. Consequently the Arg bioavailability and Orn/Cit ratio
were similar in the two groups (Figure 2B).
Mean levels of ADMA and SDMA, instead, were significantly
greater in RBCs of CAD patients compared to Ctrl (Figure 2C).
Tables 2 and 3 show the correlation pattern between plasma
and RBC analytes involved in NO biosynthesis in CAD patients
and in Ctrl. Even if many of the analytes were significantly
associated in both groups (Table 2), after mutual adjustment
several correlations disappeared (Table 3). Interestingly, a
significant and independent correlation between Cit levels in
RBCs and in plasma was found in both groups.
RBC-NO synthase expression
Confocal microscopy of washed RBCs revealed a distinct ring
of immunofluorescence staining surrounding the cytoplasm of
RBCs and, to a lesser extent, punctuate immunofluorescence
structure through the entire cytoplasm (Figure 3A and B from
CAD patients and Ctrl, respectively). Median fluorescence
intensity was significantly lower in CAD patients than in Ctrl
(Figure 3C).
RBC-NO synthase activity
The activity of RBC-NOS in vitro was tested by measuring the
hydrolysis of the L-[15N2]arginine to the labeled product L-
[15N]citrulline, which during the reaction is produced in
equimolar amounts as NO. After incubation of RBCs with L-
[15N2]arginine a marked accumulation of Orn was found (about
160% increase in both groups, corresponding to a mean increment
over basal of 26.368.3 and of 29.169.8 mmol/106 cells in CAD
patients and Ctrl, respectively, p = 0.001 for both). These data
documented the predominant activity of arginase vs NOS in
RBCs.
In the presence of arginase inhibitor Nor-NOHA the RBC-
NOS activity, assessed by the ratio between the L-[15N]citrulline
and residual L-[15N2]arginine, was significantly reduced in CAD
with respect to Ctrl (ratio geometric mean and 95% confidence
interval: 0.78, 0.54–1.15 vs. 1.45, 0.83–2.57 for CAD and Ctrl
respectively, P= 0.049), (Figure 4).
Table 1. Demographic and clinical characteristics of CAD
patients and Ctrl subjects.
Variable CAD (n=22)Ctrl (n =20) P value
Age (years) 66.168.6 55.5610.2 0.002
Male gender 17(77.3) 14(70) 0.592
BMI 27.363.11 24.3662.35 0.005
Total cholesterol (mg/dL) 208.3629.2 208.1626.8 0.95
HDL-cholesterol (mg/dL) 46.9617.2 54.5617.3 0.2
LDL-cholesterol (mg/dL) 133.8636.8 132.3622.1 0.91
Triglycerides (mg/dL) 131.5669.4 95.5632.5 0.11
Systolic Blood pressure (mmHg) 138.9618.3 130614 0.08
Diastolic Blood pressure (mmHg) 80.069.1 7866 0.4
Creatinine (mg/dL) 0.8660.22 0.8160.14 0.46
Current Smoker 3(13.64) 0(0) 0.12
HyperCholestolemia 14(63.6) 2(10.0) 0.0004
IperTrygliceridemia 2(9.1) 1(5.0) 0.75
Hypertension 14(63.6) 2(10.0) 0.0004
Pharmacological treatments
Converting enzyme inhibitors 6(27.3) 0(0)
Antiplatelets 4(18.2) 0(0)
Aspirin 13(59.1) 0(0)
Beta-Blockers 5(22.7) 1(5.0)
Calcium channel blockers 4(18.2) 1(5.0)
Diuretics 2(9.1) 0(0)
Statins 14(63.6) 2(10.0)
Hypoglycemics 0(0) 0(0)
Angiotensin receptor blockers 6(27.3) 0(0)
Quantitative variables were expressed as mean 6 SD and categorical variables
as n (%).
P value: Wilcoxon test for continous variables and Chi Square test for
categorical variables.
P value adjusted for sex and age after log-transformation of the data.
doi:10.1371/journal.pone.0066945.t001
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Oxidative stress in RBCs
Whole blood of CAD patients had lower GSH levels than that
of Ctrl (5.9760.3 and 7.7060.3 mM/g Hb, mean6SE, respec-
tively, P,0.0001) and higher levels of GSSG (0.6260.04 and
0.2960.04 mM/g Hb, mean6SE, respectively, P,0.0001). The
GSSG/GSH ratio, recognized index of oxidative stress [24,25],
was accordingly greater in CAD patients than in Ctrl (0.1160.01
and 0.0460.001 respectively, P,0.0001), which documents a
higher level of oxidative stress in RBCs of CAD patients. Finally, a
positive correlation between the GSSG/GSH and Orn/Cit ratios
(r = 0.56, P= 0.007) was found in RBCs of CAD patients.
Discussion
Alterations of RBC compartment associates with a poor
prognosis in patients with coronary disease and plasma hemoglo-
bin is an independent predictor of major adverse cardiovascular
events in patients with acute coronary syndromes [26,27]. Initially,
it was hypothesized that RBCs serve as scavengers or transporters
for NO produced by endothelial cells [28] but, recently, an active
role of RBCs in NO biosynthesis has been recognized [5].
In this study we have investigated the overall metabolic pathway
involved in NO biosynthesis in RBCs and we have measured the
levels of products involved in this pathway in plasma. We report
here unprecedented data that depict an impairment of NO
biosynthetic pathway in RBCs of CAD patients, compared to
those of healthy subjects. This impairment might be partially
ascribed to the higher levels of ADMA and SDMA in RBCs from
CAD compared to Ctrl. Increased levels of ADMA and SDMA in
plasma of patients with cardiovascular disease have been
previously reported by others and by our group [29–31]. The
impaired renal function of CAD patients has been considered to
Figure 1. Plasma levels of analytes involved in Arginine/NO pathway. (A) L-arginine (Arg), L-citrulline (Cit), L-ornithine (Orn) were
simultaneously determined by LC-MS/MS. (B) Arg bioavailability and the relative activity of arginase and NOS enzymes are expressed as Arg/(Orn+Cit)
and Orn/Cit ratios, respectively. (C) The endogenous inhibitors asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) were
determined by LC-MS/MS. (D) Tetrahydrobiopterin (BH4) and oxidized biopterins (Box) were detected by HPLC after selective oxidation with iodine.
Data are presented as age and sex adjusted geometric means and 95% C.I. Comparisons between groups (CAD, n = 22; Ctrl, n = 20) were performed
by covariance analysis, adjusting for age and sex.
doi:10.1371/journal.pone.0066945.g001
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be the main reason for these findings [3,32]. Patients in this study,
however, had a renal function within the normal range, and,
accordingly, plasma levels of SDMA were similar to Ctrl. Instead,
RBC levels of SDMA in these patients were significantly greater
than in Ctrl.
Concerning the other factors involved in NO biosynthesis,
several observations were done. First, Arg bioavailability, e.g. Arg/
Orn+Cit, and the Orn/Cit ratio were comparable between
patients and Ctrl in RBCs, but not in plasma. This finding points
out toward a potential dynamic equilibrium, which is relevant in
order to maintain intracellular homeostasis. The higher levels of
Orn in plasma of CAD patients reflect the preponderance of the
metabolic pathway that transforms Arg into Orn.
Finally, Cit levels were similar in patients and in controls both in
plasma and in RBCs. In this context it is of relevance to underline
that Cit may derive not only from the activity of NOS on Arg, but
also from that of dimethyl arginine dimethylaminohydrolase
(DDAH) on ADMA. It should be noted, however, that these
pathways supply only a minor fraction of plasma Cit as its major
source is the small intestine [33]. Indeed, in our opinion, the lack
of difference in Cit levels between patients and Ctrl is due to a
continuous exchange between the cellular and plasma compart-
ments, rather than to a direct effect of the degradation of ADMA,
as the presence of DDAH in RBCs is controversial [9,34]. Indeed,
a positive correlation between the plasmatic level and the RBC
content of Cit was observed.
The assessment of the NO pathway in RBCs has to take into
account the expression and activity of the NO synthase enzyme. In
agreement with previous studies, we detected the presence of NOS
in RBCs mainly in the membrane compartment, and this
compartmentalization might be relevant for the export of NO
toward other cells or to plasma, as previously suggested by
Figure 2. RBC levels of analytes involved in Arginine/NO pathway. (A) L-arginine (Arg), L-citrulline (Cit), L-ornithine (Orn) were
simultaneously determined by LC-MS/MS. (B) Arg bioavailability and the relative activity of arginase and RBC-NOS enzymes are expressed as Arg/
(Orn+Cit) and Orn/Cit ratios, respectively. (C) The endogenous inhibitors asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine
(SDMA) were determined by LC-MS/MS. (D) Tetrahydrobiopterin (BH4) and oxidized biopterins (Box) were detected by HPLC after selective oxidation
with iodine. Data are presented as age and sex adjusted geometric means and 95% C.I. Comparisons between groups (CAD, n = 22; Ctrl, n = 20) were
performed by covariance analysis, adjusting for age and sex.
doi:10.1371/journal.pone.0066945.g002
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Cortese-Krott et al [14]. In addition, intracellular NO in RBCs
could induce electromechanical modifications of proteins and
lipids/lipoproteins present in the membranes, thus preventing NO
consumption by RBCs [35]. Although the presence of NOS in
RBCs has been confirmed, data concerning the activity of this
enzyme are still controversial [5,11,14,36,37]. However variable
experimental conditions and methodological shortcomings were
reported. For instance, Kang et al [37] carried out the study in
homogenized cell fractions and it is possible that cofactors
necessary for NOS activity such as FAD and BH4 are lost during
homogenization as suggested by Mehta [38]. Bohmer [36] did not
find a functional RBC-NOS but he didn’t take into consideration
the activity of arginase.
In our study NOS activity in RBCs was measured in cell lysates,
in order to preserve the whole metabolic cellular system, by the
formation of L-[15N]citrulline in vitro, after the inhibition of
arginase. Indeed, arginase, by competing with NOS for the
substrate Arg, can limit its availability for NO biosynthesis in
intact cells. Although the affinity of Arg is much higher for purified
NOS (Km approximately 2–20 mM) than for arginase (Km
approximately 2–20 mM), the maximum activity of arginase at
physiological pH is 1000-fold greater than that of NOS [39].
Indeed, overexpression of the two isoforms of arginase (isoforms 1
and 2) in endothelial cells has been reported to suppress NO
generation [40], which suggests that the inhibition of the two
arginase isoforms is associated with an increase of NO biosynthesis
by endothelial cells [41]. In addition, in coronary arteries of
diabetic rats, an increased arginase activity resulted in a reduced
bioavailability of Arg as a substrate for eNOS [42]. The
importance of endothelial arginase in different pathological
conditions as hypertension, diabetes , ischaemia-reperfusion, cystic
fibrosis, sickle cell disease and asthma has already been reported
[43]. Indeed, in RBCs of hypertensive patients, increased arginase
activity accompanied by reduced levels of nitrite and nitrates was
found [44].
Overall, increased arginase activity in endothelial cells has been
proposed to promote a proatherogenic effect due to the reduction
of cell NO biosynthesis [45]. Accordingly, our data show that in
RBCs the substrate Arg is preferentially metabolized by the
arginase enzyme as documented by the selective increase in Orn
levels after the addition to RBCs of L-[15N2]arginine. This
predominant activity of arginase might explain the apparent
inconsistency of our data with those previously published by
others, which reported that NOS enzyme in RBCs is inactive
[36,37].
Interestingly, we found that the lower expression of NOS
detected by confocal microscopy in RBCs of CAD patients went in
parallel with a reduced activity of the enzyme. We cannot exclude
the effects of pharmacological treatments, ongoing in the patients,
on NOS activity that can be the result of the reduced expression of
Figure 3. Immunostaining of NO synthase (NOS) protein in human red blood cells (RBCs). NOS was detected in RBCs from CAD patients
(A) and from Ctrl (B). RBCs were incubated with a monoclonal anti eNOS antibody (2.5 mg/ml) and with an anti-mouse conjugated secondary
antibody (40 mg/ml; Alexa Fluor488). The samples were mounted with fluorescent mounting medium and examined by laser scanning confocal
microscope (LSM710, Carl Zeiss) using a 636/1.3 oil immersion objective lens. Fluorescent images were captured with a digital camera using the
image processor Zen (Carl Zeiss). (C) Fluorescence intensity (densitometric sum of grey) was quantified. Data are expressed as the log median of total
fluorescence intensity per field 6 interquartile range subtracted of the negative control value. Means derive from n=10 CAD and n= 10 Ctrl.
doi:10.1371/journal.pone.0066945.g003
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the enzyme and/or of the increased levels of ADMA and SDMA.
Indeed some authors evidenced that an angiotensin converting
enzyme inhibitor, lisinopril, monotheraphy or combined with
statin therapy, decreases arginase activity in RBCs [44]. In
addition statins [46] and aspirin [47] were described to induce
NOS activity in RBC in vivo. On these bases, these drugs could
result in an increase of NO RBC production masking a more
conspicuous difference in CAD vs Ctrl.
Arg metabolic pathway may be impaired by the occurrence of
oxidative stress, which in turn stimulates arginase activity [43] and
conversely inhibits NOS activity [48,49]. Indeed, in agreement
with previous studies [17,50,51], we found reduced levels of GSH
in CAD patients. The positive correlation between GSSG/GSH
and Orn/Cit found in our patients further supports the
predominant activation of arginase over NOS activation in the
presence of oxidative stress.
In conclusion our study shows for the first time that RBCs of
CAD patients have an impairment of the NO pathway,
decreased NOS expression/activity and increased oxidative
stress. Therapeutic interventions aimed at reducing intracellular
oxidative stress, e.g. restoration of GSH levels, might be
effective in improving the balance between NOS and arginase
activities.
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